Search

Your search keyword '"Uterine Cervical Neoplasms virology"' showing total 10,889 results

Search Constraints

Start Over You searched for: Descriptor "Uterine Cervical Neoplasms virology" Remove constraint Descriptor: "Uterine Cervical Neoplasms virology"
10,889 results on '"Uterine Cervical Neoplasms virology"'

Search Results

1. Meeting report: Considerations for trial design and endpoints in licensing therapeutic HPV16/18 vaccines to prevent cervical cancer.

2. Investigation of the Efficacy of Nowarta110 in the Treatment of HPV-16 and HPV-18 Oncogenically-transformed Human Cells and Cancer-implanted Animal Models.

3. Comprehensive Clinicopathological and Immunohistochemical Analysis of Human Papillomavirus-independent Squamous Cell Carcinoma and Adenosquamous Carcinoma of the Uterine Cervix.

4. Alternatives to surveillance for persistent human papillomavirus after a positive cervical screen: A systematic review and meta-analysis.

5. Low CD86 expression is a predictive biomarker for clinical response to the therapeutic human papillomavirus vaccine IGMKK16E7: results of a post hoc analysis.

6. Optimization of HPV-positive women triage with p16/Ki67 dual staining cytology in an organized cervical cancer screening program in the center region of Portugal.

7. Comparative analysis of Paiteling a traditional Chinese medicine (TCM) and CO2 laser therapy for high-risk HPV-associated with LSIL (CIN1) lesions.

8. The impact of Germany's human papillomavirus immunization program on HPV-related anogenital diseases: a retrospective analysis of claims data from statutory health insurances.

9. Does HPV-18 co-infection increase the risk of cervical pathology in individuals with HPV-16?

10. Genital infections in high-risk human papillomavirus positive Paraguayan women aged 30-64 with and without cervical lesions.

11. Knowledge and acceptability of the human papillomavirus vaccine and associated factors among adolescent girls in public primary schools in Dessie Town, South Wollo, Northeast Ethiopia, 2020: A cross-sectional study.

12. High-grade cervical disease and cervical cancer in women aged 50 years and older compared with younger women: examining prevalence by HIV status in two large prospective cohorts in Botswana.

13. A novel methylation-detection panel for HPV associated high-grade squamous intraepithelial lesion and cervical cancer screening.

14. Influence of COVID-19 pandemic on prevalence and genotype distribution of HPV in cervical cancer screening population.

15. High-risk human papillomavirus testing for cervical cancer screening in Uganda: Considering potential harms and benefits in a low-resource setting.

16. Factors associated with positive human papillomavirus (HPV) test results in cervical precancer screening: a cross-sectional study at Souro Sanou National Teaching Hospital (SSNTH) in Bobo Dioulasso, Burkina Faso.

17. Comparing the distribution of common human papillomavirus genotypes among the population of Fars province in southwest Iran with the genotypes included in the available HPV vaccines.

18. Susceptibility of HPV-18 Cancer Cells to HIV Protease Inhibitors.

19. Influence of cervical treatment methods on subsequent vaginal lesions: A study of HPV-related neoplasia.

20. High-risk human papillomavirus diversity among indigenous women of western Botswana with normal cervical cytology and dysplasia.

21. Prevalence of high-risk human papillomavirus genotypes and viral load correlated with squamous cell inflammation among women in Gabon.

22. Research progress on human papillomavirus-negative cervical cancer: A review.

23. Spatial distribution and characteristics of women reporting cervical cancer screening in Malawi: An analysis of the 2020 to 2021 Malawi Population-based HIV Impact Assessment survey data.

24. HPV16 E6-induced M2 macrophage polarization in the cervical microenvironment via exosomal miR-204-5p.

25. Early detection of cervical tumor cell of origin through Oncogene-induced senescent HPV-positive cells.

26. Epidemiological study of human papillomavirus infection in 105,679 women in Wuhan, China.

27. Switching from a 2-dose to a 1-dose program of gender-neutral routine vaccination against human papillomavirus in Canada: a mathematical modelling analysis.

28. Oncolytic activity of a coxsackievirus B3 strain in patient-derived cervical squamous cell carcinoma organoids and synergistic effect with paclitaxel.

29. Lineage and sublineage analysis of human papillomavirus type 58 in iranian women.

30. Clinical validation of the Roche cobas HPV test on the Roche cobas 5800 system for the purpose of cervical screening.

31. Clinicopathological and immune characterization of mismatch repair deficient endocervical adenocarcinoma.

32. A Systematic Review of Cervical Cancer Mobile Applications and a Future Directions for Developers.

33. Alterations in miRNA Expression and Their Role in the Pathogenesis of Cervical Cancer.

34. Trends in high-risk human papillomavirus infection and cervical cytology of women in Karamay City, 2012-2021.

35. The Sansure® Human Papillomavirus DNA Diagnostic Kit offers excellent reproducibility performance for the detection of high-risk HPV.

36. LAMP-based electrochemical platform for monitoring HPV genome integration at the mRNA level associated with higher risk of cervical cancer progression.

37. Risk-stratified management of cervical high-grade squamous intraepithelial lesion based on machine learning.

38. Recombinant adenoviruses expressing HPV16/18 E7 upregulate the HDAC6 and DNMT3B genes in C33A cells.

39. Prevalence and Description of High-Grade Intraepithelial Lesions of Cervical Mucosa Cells in a Screening Programme for Cervical Cancer in Isère, France.

40. Cost-Effectiveness of Computer-Assisted Cytology in a Primary hrHPV-Based Cervical Cancer Screening Programme.

41. Optimizing Protection Against HPV-Related Cancer: Unveiling the Benefits and Overcoming Challenges of HPV Vaccination.

42. Cost-Effectiveness of 9-Valent HPV Vaccination for Patients Treated for High-Grade Cervical Intraepithelial Neoplasia in the UK.

43. HPV Infection and Prevention in Patients With Immune-Mediated Inflammatory Diseases: A Scoping Review.

44. Human papillomavirus self-sampling and urine-sampling tests and the management and short-term outcomes of cervical intraepithelial neoplasia: A prospective observational study.

45. Continued suboptimal HPV vaccine coverage in the USA.

46. Carcinogenesis and epidemiology of cervical cancer: The hallmark of human papillomavirus-associated cancer.

47. Cervical Cancer Evades the Host Immune System through the Inhibition of Type I Interferon and CXCL9 by LIF.

48. Cervical cancer in Malaysia.

49. The Clinicopathological and Molecular Characteristics of Endocervical Gastric-Type Adenocarcinoma and the Use of Claudin18.2 as a Potential Therapeutic Target.

50. Unlocking Japan's cervical cancer prevention deadlock.

Catalog

Books, media, physical & digital resources